Filtered By:
Drug: Metformin

This page shows you your search results in order of relevance. This is page number 10.

Order by Relevance | Date

Total 6422 results found since Jan 2013.

Fight Aging! Newsletter, November 18th 2019
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - November 17, 2019 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
Conclusions: Oral semaglutide appears safe and effective as monotherapy and add-on pharmacological therapy for the treatment of T2DM. PMID: 31744308 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - November 18, 2019 Category: Drugs & Pharmacology Authors: Cowart K Tags: Ann Pharmacother Source Type: research

Guideline No. 392-Classification and Management of Endometrial Hyperplasia.
Authors: Auclair MH, Yong PJ, Salvador S, Thurston J, Colgan TTJ, Sebastianelli A Abstract OBJECTIVE: The aim of this guideline is to aid primary care physicians and gynaecologists in the initial evaluation of women with suspected endometrial hyperplasia, to recommend the use of the 2014 World Health Organization classification for endometrial hyperplasia by all health care providers, and to guide the optimal treatment of women diagnosed with endometrial hyperplasia. INTENDED USERS: Physicians, including gynaecologists, obstetricians, family physicians, general surgeons, emergency medicine specialists; nurses, ...
Source: Journal of Obstetrics and Gynaecology Canada : JOGC - December 3, 2019 Category: OBGYN Tags: J Obstet Gynaecol Can Source Type: research

Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
CONCLUSIONS: Metformin compared with placebo or diet and exercise reduced or delayed the risk of T2DM in people at increased risk for the development of T2DM (moderate-quality evidence). However, metformin compared to intensive diet and exercise did not reduce or delay the risk of T2DM (moderate-quality evidence). Likewise, the combination of metformin and intensive diet and exercise compared to intensive diet and exercise only neither showed an advantage or disadvantage regarding the development of T2DM (very low-quality evidence). Data on patient-important outcomes such as mortality, macrovascular and microvascular diabe...
Source: Cochrane Database of Systematic Reviews - December 2, 2019 Category: General Medicine Authors: Madsen KS, Chi Y, Metzendorf MI, Richter B, Hemmingsen B Tags: Cochrane Database Syst Rev Source Type: research

Declan Doogan of Juvenescence Presenting at Investing in the Age of Longevity
Investing in the Age of Longevity was an event held in London earlier this year as a part of the Longevity Week, a chance for Jim Mellon and the rest of the Juvenescence team to present their thesis on the longevity industry to the investor community - that this is an enormous opportunity to both greatly improve the human condition and generate returns on investment. A number of companies were there to present, as examples of the work on slowing and reversing aging presently taking place, and I was graciously invited to discuss the latest developments at Repair Biotechnologies. The presentations from the event have been po...
Source: Fight Aging! - December 16, 2019 Category: Research Authors: Reason Tags: Healthy Life Extension Community Source Type: blogs

Effectiveness of Pharmacologic Interventions in the Management of Weight Gain in Patients With Severe Mental Illness: A Systematic Review and Meta-Analysis.
Conclusions: Metformin and topiramate were the most-studied agents for weight control in SMI and were considered efficacious and safe in promoting weight reduction compared to placebo in this population. More studies are required with larger sample sizes and in line with the recommendations from research from the obesity and metabolic field to better define guidelines for use of pharmacologic interventions to reduce weight gain in patients with SMI. PMID: 31856432 [PubMed - in process]
Source: The Primary Care Companion for CNS Disorders - December 21, 2019 Category: Primary Care Tags: Prim Care Companion CNS Disord Source Type: research

Fight Aging! Newsletter, December 23rd 2019
In this study, by adenovirus-mediated delivery and inducible transgenic mouse models, we demonstrate the proliferation of both HCs and SCs by combined Notch1 and Myc activation in in vitro and in vivo inner ear adult mouse models. These proliferating mature SCs and HCs maintain their respective identities. Moreover, when presented with HC induction signals, reprogrammed adult SCs transdifferentiate into HC-like cells both in vitro and in vivo. Finally, our data suggest that regenerated HC-like cells likely possess functional transduction channels and are able to form connections with adult auditory neurons. Epige...
Source: Fight Aging! - December 22, 2019 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

A Systematic Review of Cost-Effectiveness of Sodium-Glucose Cotransporter Inhibitors for Type 2 Diabetes
The objective of this review was to evaluate the most updated evidence that examined the cost-effectiveness of SGLT2i for T2DM.Recent FindingsWe systematically searched Medline (PubMed), EMBASE, and Web of Science for eligible articles from January 1, 2011, to October 31, 2019, using combinations of search words. A supplementary search using reference lists of eligible articles and other review articles was also performed. A multistage screening process was carried out with duplicates removal, abstract screening, and full-text reading to confirm eligibility. Two reviewers independently screened the eligible articles and as...
Source: Current Diabetes Reports - March 11, 2020 Category: Endocrinology Source Type: research

Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics
AbstractFasting hyperglycemia, impaired glucose tolerance, prediabetes, and diabetes are frequently present in patients treated with second-generation antipsychotics (SGAPs) for schizophrenia, bipolar disorder, and other severe mental illnesses. These drugs are known to produce weight gain, which may lead to insulin resistance, glucose intolerance, and metabolic syndrome, which constitute important risk factors for the emergence of diabetes. The aim of this review was to formulate therapeutic guidelines for the management of diabetes in patients treated with SGAPs, based on the association between SGAP-induced weight gain ...
Source: Drugs - September 14, 2020 Category: Drugs & Pharmacology Source Type: research

Fight Aging! Newsletter, December 21st 2020
In this study, we have found that administration of a specific Sgk1 inhibitor significantly reduces the dysregulated form of tau protein that is a pathological hallmark of AD, restores prefrontal cortical synaptic function, and mitigates memory deficits in an AD model. These results have identified Sgk1 as a potential key target for therapeutic intervention of AD, which may have specific and precise effects." Targeting histone K4 trimethylation for treatment of cognitive and synaptic deficits in mouse models of Alzheimer's disease Epigenetic aberration is implicated in aging and neurodegeneration. Using p...
Source: Fight Aging! - December 20, 2020 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Fight Aging! Newsletter, January 18th 2021
In this study, Desferal, deferoxamine mesylate for injection, which is approved for the treatment of acute iron intoxication and chronic iron overload, was used to explore the beneficial effects on preventing aging-induced bone loss and mitigating dysfunction of aged BMSCs. High-dose Desferal significantly prevented bone loss in aged rats. Compared with controls, the ex vivo experiments showed that short-term Desferal administration could promote the potential of BMSC growth and improve the rebalance of osteogenic and adipogenic differentiation, as well as rejuvenate senescent BMSCs and revise the expression of stemness/se...
Source: Fight Aging! - January 17, 2021 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Targeting impaired nutrient sensing with repurposed therapeutics to prevent or treat age-related cognitive decline and dementia: a systematic review
CONCLUSIONS: Modulation of nutrient sensing pathway therapeutics, particularly growth hormone secretagogues, have the potential to improve cognitive outcomes. Overall, there is a clear lack of translation from animal models to human populations.PMID:33609776 | DOI:10.1016/j.arr.2021.101302
Source: Ageing Research Reviews - February 20, 2021 Category: Genetics & Stem Cells Authors: Benjamin Kioussis Camilla S L Tuttle Daniel S Heard Brian K Kennedy Nicola T Lautenschlager Andrea B Maier Source Type: research

Guidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option
CONCLUSION: There are treatments available for antipsychotic-induced hyperprolactinemia in patients who are unable to alter their current antipsychotic regimen. However, there remains a need for additional short- and long-term studies to determine the efficacy and safety of these treatment strategies, given that patients taking antipsychotics typically require chronic, life-long treatment for their illnesses.PMID:33631819 | DOI:10.1093/ajhp/zxab065
Source: American Journal of Health-System Pharmacy : AJHP - February 25, 2021 Category: Drugs & Pharmacology Authors: Matthew M Rusgis Afaq Y Alabbasi Leigh Anne Nelson Source Type: research

Mechanisms and Potential Roles of Glucose-Lowering Agents in COVID-19: A Review
CONCLUSIONS: Certain glucose-lowering agents may offer additional benefits beyond glucose control-namely, by modulating the mechanisms contributing to adverse outcomes related to COVID-19 in patients with diabetes. DPP-IV inhibitors and metformin appear to have the most promise. However, current published literature on diabetes medications and COVID-19 should be interpreted with caution. Most published studies are retrospective and consist of convenience samples, and some lack adequate analytical approaches with confounding biases. Ongoing trials aim to evaluate the effects of glucose-lowering agents in reducing the severi...
Source: The Annals of Pharmacotherapy - March 4, 2021 Category: Drugs & Pharmacology Authors: Helen D Berlie Pramodini B Kale-Pradhan Tara Orzechowski Linda A Jaber Source Type: research